{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:43:22Z","timestamp":1783691002466,"version":"3.55.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>There is limited understanding of the extent to which mucosa-associated lymphoid tissue (MALT) lymphoma affects a patient\u2019s risk of death and how classically considered prognostic factors affect lymphoma-specific vs other noncancer mortality. This study analyzed major long-term outcomes of patients with MALT lymphoma and the prognostic significance of baseline clinical features. We reviewed the clinical features, treatments, disease course, and survival of 593 patients with MALT lymphoma diagnosed at Memorial Sloan Kettering between 2000 to 2012. Outcomes were analyzed using crude overall survival (OS) and relative survival (RS) by standardized mortality ratio. The median age was 60 years, 72% were at stage I\/II. With a median follow-up of 9.2 years, the 10-year OS, lymphoma-specific mortality, and competing nonlymphoma mortality was 75%, 4%, and 21%, respectively; the overall standardized mortality ratio was 1.41 (95% confidence interval, 1.19-1.67; P\u00a0&amp;lt; .001). Using multivariate analysis, older age, advanced stage, and poor performance status were independently associated with inferior OS. Several subgroups had similar RS to the normal matched population, including those with an age of \u226570 years, stage I, and skin or gastric origin. Increased lymphoma-specific death was associated with spread disease, whereas death from nonlymphoma causes was correlated with older age. Overall, a diagnosis of MALT lymphoma was associated with moderately compromised survival. Age and advanced-stage disease emerged as the most important prognostic factors. Younger patients had better OS but worse RS. Disease dissemination was the lymphoma-specific risk factor.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007772","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T18:45:37Z","timestamp":1668797137000},"page":"1496-1506","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Predictors of survival in patients with MALT lymphoma: a\u00a0retrospective, case-control study"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0921-8052","authenticated-orcid":false,"given":"Shunan","family":"Qi","sequence":"first","affiliation":[{"name":"1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-4898","authenticated-orcid":false,"given":"Ariela","family":"Noy","sequence":"additional","affiliation":[{"name":"3Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"4Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisun","family":"Lee","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sewit","family":"Teckie","sequence":"additional","affiliation":[{"name":"5Department of Radiation Oncology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Hajj","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-289X","authenticated-orcid":false,"given":"Erel","family":"Joffe","sequence":"additional","affiliation":[{"name":"3Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1281-5915","authenticated-orcid":false,"given":"Brandon S.","family":"Imber","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Yahalom","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"4Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"issue":"5","key":"2023042114594012900_bib1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ajh.25446","article-title":"Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation","volume":"94","author":"Alderuccio","year":"2019","journal-title":"Am J Hematol"},{"issue":"16","key":"2023042114594012900_bib2","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.25226","article-title":"Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy","volume":"116","author":"Goda","year":"2010","journal-title":"Cancer"},{"issue":"34","key":"2023042114594012900_bib3","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1200\/JCO.18.00138","article-title":"Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution","volume":"36","author":"Alderuccio","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023042114594012900_bib4","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","article-title":"Histologic transformation in marginal zone lymphomasdagger","volume":"26","author":"Conconi","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"2023042114594012900_bib5","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A\u00a0MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2023042114594012900_bib6","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/annonc\/mdx025","article-title":"Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma","volume":"28","author":"Teckie","year":"2017","journal-title":"Ann Oncol"},{"issue":"20","key":"2023042114594012900_bib7","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/bloodadvances.2021004939","article-title":"Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?","volume":"5","author":"Imber","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"2023042114594012900_bib8","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2023042114594012900_bib9","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023042114594012900_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study","volume":"31","author":"Zucca","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023042114594012900_bib11","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2002-04-1279","article-title":"Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"101","author":"Zucca","year":"2003","journal-title":"Blood"},{"issue":"19","key":"2023042114594012900_bib12","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1200\/JCO.2006.06.0723","article-title":"Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience","volume":"24","author":"Raderer","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023042114594012900_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3324\/haematol.11835","article-title":"Dissemination patterns in non-gastric MALT lymphoma","volume":"93","author":"de Boer","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"2023042114594012900_bib14","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023042114594012900_bib15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijrobp.2015.01.040","article-title":"Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent","volume":"92","author":"Teckie","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"49","key":"2023042114594012900_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jncimonographs\/lgu024","article-title":"Cancer survival: an overview of measures, uses, and interpretation","volume":"2014","author":"Mariotto","year":"2014","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"issue":"27","key":"2023042114594012900_bib17","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2023042114594012900_bib18","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.ejca.2011.03.011","article-title":"Choosing the relative survival method for cancer survival estimation","volume":"47","author":"Hakulinen","year":"2011","journal-title":"Eur J Cancer"},{"issue":"3","key":"2023042114594012900_bib19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ijrobp.2013.11.225","article-title":"Radiation therapy administration and survival in stage I\/II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"88","author":"Olszewski","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2023042114594012900_bib20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/annonc\/mdt507","article-title":"Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma","volume":"25","author":"Meyer","year":"2014","journal-title":"Ann Oncol"},{"issue":"8","key":"2023042114594012900_bib21","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/cancers13081803","article-title":"Treatments and outcomes in stage I extranodal marginal zone lymphoma in the United States","volume":"13","author":"Alderuccio","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2023042114594012900_bib22","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.2019001088","article-title":"Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study","volume":"134","author":"Luminari","year":"2019","journal-title":"Blood"},{"issue":"21","key":"2023042114594012900_bib23","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2015.65.4194","article-title":"Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia","volume":"34","author":"Hapgood","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2023042114594012900_bib24","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.30795","article-title":"Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: a study report from the Spanish Lymphoma Oncology Group","volume":"123","author":"Provencio","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"2023042114594012900_bib25","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2023042114594012900_bib26","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023042114594012900_bib27","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma International Prognostic Index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"issue":"21","key":"2023042114594012900_bib28","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A\u00a0prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"35","key":"2023042114594012900_bib29","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1200\/JCO.20.00264","article-title":"Cause-specific mortality following initial chemotherapy in a population-based cohort of patients with classical Hodgkin lymphoma, 2000-2016","volume":"38","author":"Dores","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2023042114594012900_bib30","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1002\/cncr.30739","article-title":"Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era","volume":"123","author":"Howlader","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"2023042114594012900_bib31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"2023042114594012900_bib32","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mds644","article-title":"Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database","volume":"24","author":"Olszewski","year":"2013","journal-title":"Ann Oncol"},{"issue":"15","key":"2023042114594012900_bib33","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2017-07-795302","article-title":"Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma","volume":"130","author":"Salar","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2023042114594012900_bib34","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"15","key":"2023042114594012900_bib35","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3Kdelta\/CK1epsilon inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/8\/1496\/2045826\/blooda_adv-2022-007772-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/8\/1496\/2045826\/blooda_adv-2022-007772-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T15:54:58Z","timestamp":1682092498000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/8\/1496\/493275\/Predictors-of-survival-in-patients-with-MALT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,4,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007772","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]}}}